Pierre Jacquet - EXACT Sciences Director
| EXAS Stock | USD 60.54 0.53 0.88% |
Director
Mr. Pierre Jacquet is Director of the Company. He is a Managing Director and Global Head of L.E.K. Consultings Healthcare practice. He has served as in a variety of leadership roles for L.E.K., including the firms Global Leadership Team, the Americas management committee and various partner operating committees since 2001. Mr. Jacquet has spent more than two decades focused on corporate strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. A former physician, he worked with Arthur D. Little from 1998 to 2000 as a manager of its pharmaceutical practice and performed business development for Genzyme in 1997. During his medical career, he was a Fellow at the Washington Cancer Institute from 1993 to 1996, where he authored over 40 publications and presentations. Mr. Jacquet has served on the Advisory Board of Life Science Cares since 2017 since 2019.
| Age | 51 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 5505 Endeavor Lane, Madison, WI, United States, 53719 |
| Phone | 608 284 5700 |
| Web | https://www.exactsciences.com |
EXACT Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0304) % which means that it has lost $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Debt To Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.41 in 2024, whereas Return On Tangible Assets are likely to drop (0.1) in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Folkert Kamphuis | Jaguar Animal Health | 57 | |
| Scott Rocklage | Pulmatrix | 60 | |
| Reed Tuckson | Acasti Pharma | 63 | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
| Jean Belanger | Acasti Pharma | N/A | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Amit Munshi | Pulmatrix | 50 | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
| Steven Gillis | Pulmatrix | 65 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| Valier Boivin | Acasti Pharma | N/A | |
| Richard Conley | Pulmatrix | 63 | |
| Gregory French | Pulmatrix | 53 | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| Akihisa Akao | Pulmatrix | 59 | |
| Terrance McGuire | Pulmatrix | 61 | |
| Zhi Yang | Jaguar Animal Health | 61 | |
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Pierre Fitzgibbon | Acasti Pharma | 60 | |
Management Performance
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0304 |
EXACT Sciences Leadership Team
Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katherine Napier, Independent Director | ||
| Sally Crawford, Independent Director | ||
| Jeffrey Elliott, CFO | ||
| Kevin Conroy, Chairman of The Board, CEO and Pres | ||
| James Doyle, Independent Director | ||
| Ana Hooker, Senior Vice President Operations | ||
| Thomas Carey, Independent Director | ||
| John Fallon, Director | ||
| Scott Johnson, Senior Vice President Research & Development | ||
| Daniel Levangie, Independent Director | ||
| Vic Parker, Head Sales | ||
| John Bakewell, CFO | ||
| Sri Kalluri, Chief Officer | ||
| Nassar Nizami, Chief Officer | ||
| William Megan, Principal Financial Officer and Sr. VP of Fin. | ||
| Scott Coward, Sr. VP and General Counsel | ||
| Pierre Jacquet, Director | ||
| Graham Lidgard, Chief Science Officer and Sr. VP | ||
| Jorge Garces, Chief Officer | ||
| Jeffrey CFA, Chief Officer | ||
| David Thompson, Lead Independent Director | ||
| Michael Wyzga, Director | ||
| Lionel Sterling, Independent Director | ||
| James Herriott, General VP | ||
| Andrew Slavitt, Director | ||
| Sarah Condella, Executive Resources | ||
| Mark Stenhouse, President Cologuard | ||
| Tim Caprez, Chief VP | ||
| Kathleen Sebelius, Director | ||
| Everett Cunningham, Chief Officer | ||
| Maneesh Arora, COO, Sr. VP and Director | ||
| Katherine Zanotti, Independent Director | ||
| Eli Casdin, Independent Director | ||
| Megan Jones, Associate Relations |
EXACT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0304 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 12.68 B | ||||
| Shares Outstanding | 183.85 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 84.89 % | ||||
| Number Of Shares Shorted | 9.89 M | ||||
| Price To Earning | (38.17) X |
Pair Trading with EXACT Sciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EXACT Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EXACT Sciences will appreciate offsetting losses from the drop in the long position's value.Moving together with EXACT Stock
| 0.75 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
Moving against EXACT Stock
| 0.62 | LFCR | Lifecore Biomedical Financial Report 6th of June 2024 | PairCorr |
| 0.6 | HOWL | Werewolf Therapeutics Earnings Call This Week | PairCorr |
| 0.54 | MBRX | Moleculin Biotech Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to EXACT Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EXACT Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EXACT Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EXACT Sciences to buy it.
The correlation of EXACT Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EXACT Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EXACT Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EXACT Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.Note that the EXACT Sciences information on this page should be used as a complementary analysis to other EXACT Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for EXACT Stock analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is EXACT Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXACT Sciences. If investors know EXACT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.13) | Revenue Per Share 13.876 | Quarterly Revenue Growth 0.17 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EXACT Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if EXACT Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EXACT Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.